BUSINESS

JCR Initiates Development of Temcell for Epidermolysis Bullosa

October 30, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

JCR Pharmaceuticals announced on October 29 that it has initiated development of its regenerative medicine product Temcell HS Injection, containing allogeneic bone marrow-derived mesenchymal stem cells, for an additional indication of epidermolysis bullosa. Epidermolysis bullosa is a genetic disease in…

To read the full story

JCR Terminates Temcell Development for Epidermolysis Bullosa
March 10, 2021
JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019

BUSINESS

Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…